
• Reported GAAP EPS of $1.45 up 9.02% YoY • Reported revenue of $5.95B up 3.66% YoY • Danaher expects its effective tax rate for the remainder of 2026 to be approximately 17.0% based on its projected mix of earnings, though the actual rate could vary due to various factors.
Bullish
Danaher achieved overall sales and earnings growth, with strong performance in its Biotechnology segment driven by increased core sales and consumables demand. The company also maintained robust operating cash flow and liquidity.
Bearish
Danaher faces declining Diagnostics segment margins and sales due to lower demand and pricing pressure. Geopolitical conflicts also present risks, alongside increased debt and transaction costs from the Masimo acquisition.